Groowe Groowe / Newsroom / NVS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

NVS News

Novartis AG

Global TDP-43 Antibody Market Outlook and Forecast, 2026-2032 - Market to Reach USD 508.93 Million at 12.03% CAGR as Validated Antibodies, AI-Powered Imaging, and Neurodegenerative Research Create New Growth Opportunities

globenewswire.com
ABBV ABT ABM BIO BIIB BMRN CRSP DHR EXAS GILD ILMN INCY ISRG JNJ LULU MDLZ MRK NVS PFE REGN ROST SNPS SRPT STX TMO TSLA VRTX WDC

Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance Competition

globenewswire.com
PFE AMGN AZN EVTC MRK NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

accessnewswire.com
NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

accessnewswire.com
NVS

Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Shareholders to Connect

accessnewswire.com
NVS

Breast Cancer Continues to Impact Communities; Austin Rallies Together to Take Action at Susan G. KomenĀ® Austin MORE THAN PINK Walk

businesswire.com
DELL BAC NTRA LLY NVS

Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research

prnewswire.com
ABBV JNJ AMGN BMY PFE NVS SNY LLY AZN UCB BIIB VTRS GILD KYMR

Global Multiple Sclerosis Treatment Market to Grow at 5.8% CAGR, Reaching USD 44.45 Billion by 2034 as Advanced Therapies and Disease-Modifying Treatments Gain Momentum, Says Maximize Market Research

prnewswire.com
NVS BIIB SNY MRK BMY JNJ TEVA VTRS AMGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

accessnewswire.com
NVS

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

globenewswire.com
ABBV ABCL AZN BIIB BMY EXEL GILD GSK INCY LRCX MRK NVS PFE REGN SNY TMO UCB VRTX